XENE Xenon Pharmaceuticals Inc.

NEUTRAL Impact: 2/10 144
Horizon days Filed Jun 5, 2026 Processed 4d 11h ago SEC 0001950047-26-005710
Form 144 — notice of proposed sale of securities

Price Chart

Loading chart...

Executive Summary

Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued at approximately $70,053 based on the filing date. This is a very small sale relative to the company's $5.1B market cap and appears to be a routine, low-conviction signal.

Actionable Insight

This is a routine, small-dollar insider sale by a director following RSU vesting. No material signal for traders. Monitor for any larger insider sales or changes in ownership patterns ahead of upcoming catalysts.

Key Facts

  • Director Gary Patou filed Form 144 to sell 1,322 shares of XENE common stock.
  • Estimated sale value is approximately $70,053 based on the filing date.
  • The shares were acquired from restricted stock units vesting on 05/31/2026.
  • The sale represents a tiny fraction of the company's $5.1B market cap.
  • No other insider sales or purchases were reported in the prior 30 days.

Financial Impact

Sale of 1,322 shares worth ~$70,053; negligible relative to $5.1B market cap.

dilution

Risk Factors

  • Insider sale intent is filed but may not be executed.
  • No material risk to stock price from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005710
Document: 0001950047-26-005710-index.html0001950047-26-005710
Document: 0001950047-26-005710.txt0001950047-26-005710
10 reports for XENE
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +7.28%Mar 13, 2026
Filters
Rows
Reports for XENE — sortable, filterable
Type Now
Jun 5, 2026
4d ago
144
NEUTRAL ★ 2/10
$51.73 awaiting T+1awaiting T+1$51.21 (−1.01%)
Jun 3, 2026
6d ago
8-K
NEUTRAL ★ 3/10
$52.99 $51.73▼ −2.38%▲ +0.22%$51.21 (−3.36%)
May 7, 2026
4w ago
Press Release
MIXED ★ 6/10
$56.44 $55.78▼ −1.17%▼ −1.40%$51.21 (−9.27%)
Apr 22, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$55.41 $55.24▼ −0.31%▼ −1.09%$51.21 (−7.58%)
Apr 19, 2026
7w ago
Press Release
BULLISH ★ 8/10
$57.09 $56.40▼ −1.21%▼ −0.56%$51.21 (−10.30%)
Apr 15, 2026
7w ago
Press Release
BEARISH ★ 5/10
$58.88 $58.43▲ +0.76%▲ +1.02%$51.21 (+13.03%)
Apr 13, 2026
8w ago
8-K
NEUTRAL ★ 3/10
$59.35 $58.88▼ −0.79%▼ −1.57%$51.21 (−13.72%)
Apr 7, 2026
9w ago
Press Release
BEARISH ★ 5/10
$57.65 $57.54▲ +0.19%▲ +2.73%$51.21 (+11.17%)
Mar 13, 2026
12w ago
Insider Cluster
BEARISH ★ 6/10
$55.23 $54.66▲ +1.03%▲ +2.06%$51.21 (+7.28%)
Mar 12, 2026
12w ago
Press Release
NEUTRAL ★ 5/10
$55.23 $54.66▼ −1.03%▼ −2.06%$51.21 (−7.28%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access